Companion Dog Arthritis Biologics Advanced

Anti-nerve growth factor biologics have transformed canine arthritis pain management - understanding their use optimises welfare outcomes.

Key Facts

Bedinvetmab (Librela) is a monthly anti-NGF injection licensed for canine osteoarthritis pain
Clinical trials showed significant improvement in pain and mobility from month 1
It provides analgesia through a different mechanism from NSAIDs enabling combination or alternative use
Some dogs show rapid dramatic responses while others have more modest improvements
Regular monitoring is recommended - repeat assessments using owner-completed mobility scales track response
NSAIDs remain important for acute pain management and for dogs not responding to biologics

Welfare Considerations

Anti-NGF biologics represent the most significant advance in canine chronic pain management in decades. They provide durable monthly pain relief without the gastrointestinal risks of NSAIDs, benefiting dogs that cannot tolerate traditional treatments. The monthly injection frequency also reduces daily medication stress compared to tablet administration.

What You Can Do

Ask your vet about Librela injections for your dog with diagnosed osteoarthritis
Use a validated mobility scoring tool monthly to assess response to treatment
Report any adverse reactions to your vet promptly including lethargy or injection site reactions
Continue environmental modifications including ramps and orthopaedic beds alongside medication
Support research into long-term outcomes and optimisation of anti-NGF therapy in dogs